Related Experiment Video
Updated: Jun 24, 2026

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse
Published on: October 25, 2024
Novel therapeutic targets along the Th17 pathway
Wenjun Ouyang1, Ellen Filvaroff, Yan Hu
1Department of Immunology, Genentech, South San Francisco, CA 94080, USA. ouyang@gene.com
The discovery of interleukin-17 (IL-17)-producing CD4(+) T helper (Th17) cells has updated the Th1/Th2 model. These cells are implicated in autoimmune diseases, offering new therapeutic targets.
Area of Science:
- Immunology
- Cellular Biology
- Autoimmunity
Background:
- The traditional Th1/Th2 dichotomy model for T helper cell subsets has been challenged.
- Interleukin-17 (IL-17)-producing CD4(+) T helper cells (Th17) represent a distinct subset.
- Th17 cells play a significant role in the development of human autoimmune diseases.
Purpose of the Study:
- To highlight the significance of Th17 cells in immunology.
- To discuss the developmental pathways of Th17 cells.
- To explore the therapeutic potential of targeting Th17 cells.
Main Methods:
- Review of recent immunological research.
- Analysis of Th17 cell differentiation and function.
- Examination of Th17 cells' role in autoimmune pathogenesis.
Main Results:
- The discovery of Th17 cells has led to a revised understanding of T helper cell subsets.
- Th17 cells are key players in the pathogenesis of various autoimmune conditions.
- The unique characteristics of Th17 cells present promising avenues for novel therapeutic strategies.
Conclusions:
- Th17 cells are a crucial subset of CD4(+) T helper cells.
- Targeting Th17 cell pathways offers potential for treating autoimmune diseases.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Tumor Immunotherapy

